Drug Profile
Research programme: diabetes and obesity therapeutics - GlaxoSmithKline/Cold Spring Harbor Laboratory
Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator Cold Spring Harbor Laboratory; GlaxoSmithKline
- Developer Cold Spring Harbor Laboratory; GSK
- Class Small molecules
- Mechanism of Action Protein tyrosine phosphatase non receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for research development in Obesity in USA (PO)
- 28 Apr 2019 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA (PO)
- 23 Mar 2015 Early research in Obesity in USA (PO)